The present invention relates to novel aminopyridine derivatives of the general formula (I) and pharmaceutical compositions comprising these compounds, as well as their therapeutic use, particularly as neuropeptide FF (NPFF) receptor antagonists, including, e.g., for the treatment or prevention of pain, opioid-induced hyperalgesia, or addiction.

##STR00001##

Herein provided is a novel recombinant CXCL10 polypeptide with increased glycosaminoglycan (GAG) binding affinity compared to wild type CXCL10 and increasing T-cell mobilization and its use for preventing or treating inflammatory and immuno-logical disorders and auto-immune diseases.

Herein provided is a novel recombinant CXCL10 polypeptide with increased glycosaminoglycan (GAG) binding affinity compared to wild type CXCL10 and increasing T-cell mobilization and its use for preventing or treating inflammatory and immuno-logical disorders and auto-immune diseases.

The present invention relates to the production of capsaicinoid compounds including Capsaicin and Nonivamide via microbial fermentation.

A method is disclosed of treating pain with senicapoc, a potent Ca.sup.2+-activated K.sup.+ channel, K.sub.Ca3.1 antagonist in CNS-resident microglia. Senicapoc is shown to cause in a decrease of IL-1β and NO release from microglia cells vivo and in vitro. Because of contribution of K.sub.Ca3.1 to neuropathological processes, senicapoc is useful in the treatment of chronic, neuropathic, visceral, and inflammatory pain and the reversal of tactile allodynia.

A method is disclosed of treating pain with senicapoc, a potent Ca.sup.2+-activated K.sup.+ channel, K.sub.Ca3.1 antagonist in CNS-resident microglia. Senicapoc is shown to cause in a decrease of IL-1β and NO release from microglia cells vivo and in vitro. Because of contribution of K.sub.Ca3.1 to neuropathological processes, senicapoc is useful in the treatment of chronic, neuropathic, visceral, and inflammatory pain and the reversal of tactile allodynia.

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

Provided are anti-tetranectin domain-specific antibodies and fragments thereof, as well as methods of use employing such antibodies and/or fragments.

Provided are anti-tetranectin domain-specific antibodies and fragments thereof, as well as methods of use employing such antibodies and/or fragments.

Provided is a pharmaceutical agent for enhancing absorption efficiency of a drug through the mucosal epithelial layer. A pharmaceutical agent for transmucosal administration comprises as an active ingredient a drug compound to which a podocalyxin targeting molecule is bound.